ArticleFrontiers in artificial intelligence2026
DrugPred: an EdgeConv-GNN and Bio_ClinicalBERT based polypharmacy ADR prediction and specialist recommendation model.
Article in Frontiers in artificial intelligence, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adverse drug reactions (ADRs) are caused by medication and are considered a serious issue in healthcare when there is simultaneous use of different medications resulting in drug-drug interaction (DDI). Traditional approaches mostly focus on the effects caused by a single drug, and they fail to capture the side effects from drug combinations. In this research work, a deep learning-based DrugPred framework is proposed to predict ADR risks by integrating individual drug effects, interaction statistics of the drugs, and structural relationships between drug-interaction graphs. In the first phase, baseline association scores between individual drugs and their corresponding ADRs, such as nausea, liver toxicity, or cardiovascular effects, are learned using a multi-layer perceptron (MLP) trained on the OFFSIDES dataset, providing probabilistic values for individual drug-ADR pairs. In the second phase, a Graph Neural Network (GNN) based on the EdgeConv architecture is utilized to model drug-drug interactions using the TwoSIDES dataset, capturing relational dependencies by utilizing pairwise statistical values such as co-occurrence frequency and interaction statistics derived from pharmacovigilance signals, including transformed PRR-based signals. In the third phase, Bio_ClinicalBERT, which is a pre-trained transformer-based language model specifically trained on clinical notes and biomedical text, is used to encode drug pair representations and combine them with association and interaction scores through an attention-guided mechanism, which enables the model to adaptively weight heterogeneous features and finally performs multi-label ADR prediction. The proposed model achieves an accuracy of 95.73%, F1-score of 0.94, ROC-AUC of 0.993, and PR-AUC of 0.988. These results indicate that our proposed DrugPred framework is effective in the prediction of ADR risks with high precision and recall. Overall, the proposed framework provides a scalable approach for predicting ADRs in multi-drug settings. We further extend our framework with a retrieval-based guidance system that maps the risk levels of the predicted ADRs to appropriate System Organ Classes (SOC) and medical specialists to provide recommendations using real-world clinical data sources like PubMed and OpenFDA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.